Introduction

Conventional oral formulations are the top leading dosage form in global market. It is the preferential route for drug administration and management. The oral controlled-release systems show a distinctive model of drug targets to liberate in which the drug absorption is sustained in the curative window for an extended phase of time, thus safeguarding sustained therapeutic action. In certain situations this release pattern isn't always appropriate that insists discharge of a drug after an interval of time. The pulsatile system is in advance quite a few attention, as the drug is launched entirely after described insulates time ([Figure 1]). PDD is website online and time-specific drug shipping, as a consequence imparting spatial and chronological shipping and accumulative patient fulfillment. This drug transport gives the fast and fleeting delivery of certain amount of selected molecules within a small span of time immediately after a programmed duration, i.e., lag time, and these system have the process of handling the drug substance quickly and completely after an insulated time. Such a release model is called as pulsatile release.^[1], ^[2], ^[3], ^[4] Human’s body show a particular circadian rhythms that are synchronized by the master circadian clock, the suprachiasmatic center. Chronopharmacotherapy of diseases (myocardial infarction, bronchial asthma, rheumatic disease, angina pectoris, ulcer and hypertension) that explain circadian rhythm in their etiology and management of such diseases entail PDDS, by which drug is released quickly and entirely as a pulse after insulate time.^[5], ^[6], ^[4] There are several other conditions that require release of the drug in pulsatile manner, like many frame capabilities that trace circadian rhythms, consisting of secretion of hormones like luteinizing hormone, follicle stimulating hormone, progesterone and estrogen, acid secretion in the gastric emptying, stomach and GI blood transfusion. There are abundant benefits of the PDDS. These are:

Can be used extensively for day and night time action.

Low cost, side effects are low as dose frequency and dose size is less.

Adapts to body circadian rhythms.

Drug targeting is easy.

Defends the GI mucosa from irritating drugs.

First pass metabolism is lease.

Steady drug level is maintained in the blood plasma.^[7], ^[8], ^[9], ^[10]

Disadvantages

Loading capacity of drug is less.

Release of drug is less.

Formulation steps are complex.

Reproducibility and efficacy is poor.

Skilled/trained persons needed for manufacturing.

Present review focus on advanced methodologies for pulsatile manufacturing and up-gradation in the technologies for manufacturing.

Chronopharmacotherapy

The phrase chronopharmaceutics includes two words chronobiology and pharmaceutics. Chronobiology is the area which includes study of biological rhythms and their mechanisms in the body. Chronotherapeutic drug shipping machine is the drug delivery device that's based at the biological rhythms of frame. Chronomodulated machine is also recognized as pulsatile device or sigmoidal release system. There are 4 styles of mechanical rhythms in our body, which manage ordinary and disease associated body structure of the body ([Figure 2]).They are:

Circadian: The oscillation is completed in 24hrs.

Ultradian: The oscillation completed in shorter duration i.e. less than 24 hrs.

Infradian: The oscillations is longer than 24 hrs.

Seasonal: In the short days of winter, seasonal affected illness reasons melancholy in prone people. Out of four biological rhythms, circadian rhythm is the main rhythms in the body which maintains all the physiological, chemical, biological and behavioral processes.^[11], ^[12], ^[13]

Necessitate of pulsatile drug delivery systems

Circadian rhythm follows many body functions which fluctuates according to the time.

Acid secretion, cholesterol synthesis, gastric emptying and GI blood transfusion might change with circadian rhythm.

Chronopharmacotherapy of illnesses which give an explanation for circadian rhythms of their path body structure.

Mechanism of drug release from pdds

The release happens from PDDS in different ways.^[14]

a) Diffusion H2O diffuses to the internal particle as soon as it comes in contact with aqueous fluids.

Erosion With time few particles erode slowly to release the drug.

Osmosis Osmotic pressure develops between the outside aqueous fluid and internal particle which can be one pathway of release of drug.

Classification of PDDS

Pulsatile system are essentially time-controlled drug delivery system in which the system manages the lag time independent of environmental factors like enzyme, pH, GI motility etc. Pulsatile drug delivery systems can be generally categorized into four classes.^[15]

Time-controlled pulsatile release system

These time-controlled systems can be classified as a single units (e.g., tablet or capsule) or multiple unit systems.

Single unit systems

Capsular systems

Single-unit systems are mostly developed in capsule form. The insulate time is managed by way of a plug, which finds pushed away by erosion or swelling and the drug is launched as a Pulse from the insoluble pill frame. Polymers used for designing of the hydrogel plug are as following: ^[16]

Swellable materials coated with but permeable polymer (polymethacrylates).

Erodible compressed polymer (polyvinyl alcohol, HPMC).

Congealed melted polymer (glyceryl mono oleate).

Enzymatically controlled erodible polymer (pectin).^[17]

These structures are made in a way that drug reservoir is covered with soluble or erodible layer that dissolves when in contact with fluid and drug is released after an insulated tiem.^[18] For instance the biological clock of body.^[19] It includes a strong dosage shape protected with lipid limitations containing surfactants.^[20] The insulate time and movement of drug is managed by the thickness and grade of viscosity of polymer ([Figure 6]).

The system is coated with a rupturable membrane. The outer layer or membrane gets ruptured due to pressure by effervescent agents. In such a system sodium bicarbonate and citric acid are used as effervescent agents.^[21] Ethyl cellulose coating is done in the core tablet when the system comes in contact with water it releases carbon dioxide which creates pressure and after some time the membrane ruptures due to pressure ([Figure 7]). The lag time is controlled by way of the composition of the outer polymeric membrane.^[22], ^[23], ^[24], ^[25]

Multiple unit pulsatile systems

Gastric emptying pattern differs for multi-particulate formulations, such system are dispersed freely throughout the GITand is affected by transit time of food^[26] ([Figure 8]). These systems are of two types.

This system incorporates the interface of some acrylic polymers with quaternary ammonium corporations. The inside core is having drug and succinic acid coated with AMC USP/NF type

The water is responsible for liquefying the succinic acid. This scheme was used to design an acid-containing core and tested in beagle dogs. It shows a good in vitro/in vivo relationship of lag time.^[27]

Stimuli-induced pulsatile release system

This system release the drug in response to stimuli by the external surroundings.^[28]

Thermoresponsive pulsatile release

Hydrogel are the better example for thermo-sensitive drug delivery. The polymer is crosslinked and the transition in temperature is linked in the formation of hydrogel. Temperature-sensitive polymer used are ethyl, methyl, and propyl groups. Poly (N-isopropyl acrylamide) (PINPAm) are extensively used polymers.^[29]

Chemical stimuli-induced pulsatile release

The factor responsible for drug release is biological factors like pH, enzymes or any other chemical stimuli. Example is automatic release of insulin when glucose level rises in blood. Kazunori et. al., reported a gel that showed a remarkable change in swelling caused by glucose using phenylboronic acid.^[30], ^[31]

Externally regulated pulsatile release system

Electro responsive pulsatile release

Application of electric field as an external stimulator. Electrically response delivery uses polyelectrolytes and are also sensitive to pH change. Poly (2-acrylamide-2-methyl propane sulfonic acid-co butyl methacrylate) hydrogels are example of such delivery system.^[32], ^[33]

Micro electro-mechanical systems

The device made by this system have the ability to store and release many chemical moiety by moving mechanism. Better control over drug release is possible. Another advancement is microchip, which contains such reservoirs of impermeable substrate through an electrolyte.^[34] Prototype microchip is made of silicon and contains drug reservoir which is covered at one end by gold that provides the electrochemical reaction and melts on application of electric potential.^[35], ^[36]

Proprietary name	Active pharmaceutical ingredient	Chronopharmaceutical technology	Drug release mechanism
Concerta® tablet	Methylphenidat HCl	Oros	Osmotic regulation
Cardizem LA	Diltiazem Hcl	Ceform microsphere technology	Diffusion/ erosion
UniphyllR	Theophylline	ContinR	Controlled release
InnopranR XL	Propranolol Hcl & Verapamil	Diffucaps	Rapid/sustained release
Covera-HSR	Verapamil	Oros	Osmotic regulation
VerelanR PM	Verapamil	Codas	Delayed release
Pepcid	Famotidine	Physicochemical modification of API	Tablet
LipovasR ,	Simvastatin	Physicochemical modification of API	Tablet
InvegaTM	Paliperidone	OROS	Osmotic regulation
Glucotrol	Glipizide	OROS	Osmotic regulation
Glizid-MR30	Gliclizide	Hydrophilic matrix technology	Swelling/diffusion/erosion
KapidexTM	Dexlansoprazole	DDR Technology	Dual drug release
Coruno®	Molsidomine	Geomatrix technology	Swelling/erosion
Theirform	Diclofenac sodium	3DP	Immediate release/controlled release
PulsincapTM	Dofetilide	PulsincapTM	Rupturable system
Moxatag®: ER tablets	Amoxicillin	Pulsystm	Multiparticulate system
Their form	Diclofenac Na	Three dimensional printing	Externally regulated system
Opana®	Oxymorphone	Timerx®	Erodible/ soluble barrier coating ER Tablets
Cardiazem® LA	Diltiazem HCl,Verapamil HCl	Ceform®	Extended Release tablet
Procardia XL	Nifedipine	Procardia XL®	Sustained release
Hokunalin® tape	Tulobuterol	Transdermal chronodelivery System.

Table 1 Example of FDA approved pulsatile drug delivery systems in market

S. No.	Based on API/Device	Topic	Inventor	Status/Date	Patent No.
1	Device	Multi-dose drug delivery device and method	Robert Farra	Granted/ 2014-03-25	US8679093B2
2	Device	Medical device for controlled drug delivery and cardiac monitoring and/or stimulation	Barry M. Yomtov Stephen J. Herman	Granted/ 2011-03-29	US7917208B2
3	Device	Low-permeability, laser-activated drug delivery device	Jonathan Robert CoppetaKenneth N. HorneJohn T. Santini, Jr.John A. SchollGregory J. R. Spooner Cynthia L. Stevenson Naveed ShamsAndrew Poutiatine	Grant/ 2014-12-16, 2014-01-08	US8911426B2, EP2533737B1
4	Device	Portable drug delivery device including a detachable and replaceable administration or dosing element	Joseph Zhili Huang Guy DiPierro	Grant/2013-02-12,	US8372040B2
5	Device& different APIs	Oral drug delivery system	Su Il YumGrant SchoenhardArthur J. TiptonJohn W. GibsonJohn C. Middleton	Grant/ 2012-03-13, 2015-09-23, 2012-02-01, 2013-06-12, 2013-09-17, 2010-11-11, 2016-01-11, 2011-01-26	US8133507B2, EP2218448B1, JP4865330B2, CN101797221B, CA2810477C, DE60334401D1, DK2218448T3, ES2350689T3
6	Delivery system	Drug delivery system	James M. Olsen	Granted/ 2010-08-03, 2007-11-14, 2008-09-11	US7766885B2, EP1755703B1, DE602005003355T2
7	Device	Cartridge insertion assembly for drug delivery system	Oz Cabiri	Granted/ 2012-04-17, 2014-08-13, 2014-07-02, 2014-05-07	US8157769B2, EP2477679B1, JP5535321B2, CN102639169B
8	Ionizable pharmaceutical agent& lipophilic species	Transmucosal drug delivery system	John A. McCarty	Granted/ 2015-03-31, 2014-04-16, 2013-01-02, 2012-02-07, 2013-07-08, 2013-07-18, 2009-01-10	US8992974B2, JP5475215B2, CN1777411B, CA2516816C, DK1599186T3, ES2414084T3, RU2342953C2
9	Devices	Drug delivery devices, kits and methods there for	Gilbert H. KLIMAN	Granted/ 2013-08-27	US8521273B2
10	Devices	Gastric retention controlled drug delivery system	Kamlesh Mohanlal DudharaNitin Bhalachandra DharmadhikariVaishali Vijay Dhavse	Granted/ 2010-08-17, 2012-12-05, 2012-08-08, 2010-12-01, 2011-06-14, 2010-09-30, 2013-03-15, 2008-05-27	US7776345B2, EP2238975B1, JP4994570B2, CN1520286B, CA2452738C, DE60237372D1, ES2398348T3, RU2325152C2
11	Device	Transmucosal drug delivery device and method including chemical permeation enhancers	Scott UhlandEric PeetersHussain Fatakdawala	Granted/2014-11-11, 2014-11-19, 2015-05-07	US8882748B2, EP2308465B8, JP5715368B2
12	Delivery System	Controlled dose drug delivery system	Amir ShojaeiStephanie ReadRichard A. CouchPaul Hodgkins	Granted/ 2014-09-30	US8846100B2

Table 2 Recent patent on pulsatile/controlled drug delivery systems/devices

Pulsatile release systems for vaccine and hormone products

The major mechanism involved in therapeutic benefit from vaccines is development of immunity.^[37] Vaccine are administered to protect the bosy and hence co-administration is also needed to maintain the immunity. ^[38] PDDS can be used for delivery of vaccines.^[38], ^[39], ^[40], ^[41], ^[42]

References

1. A Kikuchi, T Okano. Pulsatile drug release control using hydrogels. Adv Drug Deliv Rev 2019. [Google Scholar]
2. JJ Santini, AC Richards, R Scheidt, MJ Cima, R Langer. Microchips as controlled drug-delivery devices. Angew Chem Int Ed Engl 2019. [Google Scholar]
3. HP James, L Sara, B Samuel, FJ Norman, MM John, C Jonathan. Programmed polypeptide delivery from an implanted, multireservoir microchip device. Nat Biotechnol 2006. [Google Scholar]
4. J Santini, MJ Cima, R Langer. A controlled-release microchip. Nature 1999. [Google Scholar]
5. SS Shidhaye, VM Lotlikar, AM Ghule, PK Phutane, VJ Kadam. Pulsatile drug delivery systems: an approach for chronotherapeutic diseases. Sys Rev Pharma 2019. [Google Scholar]
6. C Amy, SC Insung, MT Betty, PW Paul, B Henry, JC Michael. Multi-pulse drug delivery froma resorbable polymeric microchip device. Nat Mater 2020. [Google Scholar]
7. WA Ritschel, H Forusz. Chronopharmacology: a review of drugs studies. Methods Find Exp Clin Pharmacol 2018. [Google Scholar]
8. RK Reddy, MV Jyothsna, TS Mohamed, C Chetty. Review on: pulsatile drug delivery systems. J Pharm Sci Res 2019. [Google Scholar]
9. SY Yang, JA Yang, ES Kim, G Jeon, EJ Oh, KY Choi. Single-file diffusion of protein drugs through cylindrical nanochannels. ACS Nano 2019. [Google Scholar]
10. S Rathod. Colon targeted pulsatile drug delivery: A review. Pharma Rev 2020. [Google Scholar]
11. J Harkness, MB Richter, A Panayi, K Pette, A Unger, R Pownall. Circadian variation in disease activity in rheumatoid arthritis. Br Med J 2020. [Google Scholar]
12. N Jha, S Bapat. Chronobiology, drug delivery, and chronotherapeutics. Kathmandu Univ Med J 2020. [Google Scholar]
13. B Botti, C Youan. Chronopharmaceutics: gimmick or clinically relevant approach to drug delivery. J Control Release 2020. [Google Scholar]
14. SL Patwekar, MK Baramade. Controlled release approach to novel multiparticulate drug delivery system. Int J Pharm Pharm Sci 2019. [Google Scholar]
15. M Bakhshaee, JS Binns, H Stevens, CJ Miller. Pulsatile drug delivery to the colon monitored by gamma scintigraphy. Pharm Res 2020. [Google Scholar]
16. JM Hebden, CG Wilson, RC Spiller, PJ Gilchrist, E Blackshaw, M Frier. Regional differences in quinine absoption from the undisturbed human colon assessed using a timed release delivery system. Pharm Res 2020. [Google Scholar]
17. J Binns, H Stevens, J Mcewen, G Pritchard, FM Brewer, A Clarke. The tolerability of multiple oral doses of pulsincap TM capsules in healthy volunteers. J Control Release 2021. [Google Scholar]
18. HNE Stevens, A Rashid, M Bakhshaee. US Patent No., US5474784A. 2021. [Google Scholar]
19. S Shidhaye, A Dhone, T Budhkar, C Surve. Technologies in pulsatile drug delivery system. Int J Adv Pharm Bio Chem 2019. [Google Scholar]
20. JR Crison, PR Siersma, D Taylor, GL Amidon. Programmable oral release technology, Port Systems & Mac226: a novel dosage form for time and site specific oral drug delivery. Proceed Intern Symp Control Rel Bioact Mater 2020. [Google Scholar]
21. AR Gennaro. Remington: The Science and Practice of Pharmacy. 2019. [Google Scholar]
22. IR Wildind, SS Davis, M Bakhshaee, HNE Stevens, RA Sparrow, J Brennan. Gastrointestinal transit and systemic absorption of captopril from a pulsed release formulation. Pharm Res 2019. [Google Scholar]
23. H Saeger, P Virley. Pulsincap & Mac226: Pulsed release dosage form. Product information from Scherer DDS. Ltd. 2018. [Google Scholar]
24. I Krögel, R Bodmeier. Floating or pulsatile drug delivery systems based on coated effervescent cores”. Int J Pharm 2019. [Google Scholar]
25. GL Amidon, GD Leesman. US Patent No. 5229131A. 2018. [Google Scholar]
26. H Bechgaard, K Ladefoged. Distribution of pellets in the gastrointestinal tract. The influence on transit time exerted by the density or diameter of pellets. J Pharm Pharmacol 2017. [Google Scholar]
27. R Yadav, S P Tiwari, J Galgano. Recent challenges in COVID 19 vaccines and its future advancements. IP Int J Comprehensive Adv Pharmacol . [Google Scholar]
28. Y Ueda, T Hata, H Yamaguchi, M Kotani, S Ueda. Development of a novel drug release system, time-controlled explosion system (TES). Part 1: concept and design. J. Drug Target 2018. [Google Scholar]
29. J Z Krezanoski. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes. US 4188373A 2018. [Google Scholar]
30. K Ishihara, M Kobayashi, N Ishimura, I Shinohara. Glucose induced permeation control of insulin through a complex membrane consisting of immobilized glucose oxidase and a poly(amine). Polym J 2018. [Google Scholar]
31. S Sershen, J West. polymeric systems for modulated drug delivery. Adv Drug Deliv Rev 2019. [Google Scholar]
32. JS Burns, H Stevens, J Mcewen, G Pritchard, FM Brewer, A Clarke. Pulsatile drug delivery system. J Control Release 2019. [Google Scholar]
33. H Saeger, P Virley. Pulsincap and Mac226: Pulsed- release dosage form. Scherer DDS, Ltd. 2019. . [Google Scholar]
34. R Yadav, M Jha, S Prasad, D Jat, D Jain. Mayaro virus (MAYV) Disease: Past, present and future. J Pharm Biol Sci 2022. [Google Scholar]
35. R Yadav, A Dubey, SP Tiwari, P Shrivastava, S Mandal. Nanotechnology and its Applications: A Scientific Boon for Future. Int J Drug Deliv Technol 2022. [Google Scholar]
36. JT Santini, AC Richards, R Schiedt, MJ Cima, R Langer. Microchips as controlled-drug delivery devices. Angew Chem Int Ed 2019. [Google Scholar]
37. G Ada. Strategies for exploiting the immune system in the design of vaccines. Mol Immunol 2019. [Google Scholar]
38. P Kashyap, SP Mishra, S Dutta, R Yadav, K Mishra, K Sahu. Traditional plant and herbs used in rural area for prevention of disease caused by water pollution. IP Int J Comprehensive Adv Pharmacol 2021. [Google Scholar]
39. M Rajput, R Sharma, S Kumar, F Jamil, N Sissodia. Pulsatile drug delivery system: a review. Int J Res Pharm Biom Sci 2019. [Google Scholar]
40. PK Patel, CK Patel. Pulsatile drug delivery system. Asian J Pharm Clin Res 2019. [Google Scholar]
41. GA Kumar, A Bhat, AP Lakshmi, K Reddy. An Overview of Stimuli-induced pulsatile drug delivery system. Int J Pharm Tech Res 2019. [Google Scholar]
42. R Yadav. An review on epidemiology, biochemical characteristics, treatment suggestions, and continued studies on diabetes and cardiovascular disease. Int J Health Sci 2022. [Google Scholar]
43. NS Dey, S Majumdar, M Rao. Multiparticulate drug delivery systems for controlled release. Trop J Pharm Res 2018. [Google Scholar]
44. RK Sahu, R Yadav, P Prasad. Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance. SpringerPlus 2014. [Google Scholar]